Simons Chase

In recent groundbreaking research, scientists have discovered that the drug Dulaglutide, commonly used to type 2 diabetes mellitus (T2DM), has shown promising results in reversing depression-like behavior and restoring metabolic balance in the hippocampus of mice subjected to chronic mild stress. This study highlights the intricate link between metabolic disorders and mental health, suggesting a … Read more

In biotech investing, distilling exceptional opportunities from the average (or worse) ventures requires a keen eye on insider activities, financial health, and clinical progress. Beam Therapeutics (BEAM) presents a case that demands caution, with insider stock sales, a substantial accumulated deficit, and limited clinical advancements raising significant concerns. In contrast, Intensity Therapeutics (INTS) is an … Read more

Biotech companies developing GLP-1 agonists for weight loss treatment are being keenly pursued by more mature pharmaceutical companies that have missed the bandwagon so far. This is because use of GLP-1s could increase by 10 – 70 million consumers by 2028, perhaps becoming the largest drug class in history. Reuters reports that the widespread use … Read more

There is a furious pace of innovation, deal flow and drug approvals for the new class of glucagon-like peptide 1 (GLP-1) receptor agonists and the emerging next gen Dual Agonists for the treatment of obesity and weight loss. Among mature pharmaceutics companies, the bandwagon took off when the sleepy backwater of GLP-1s for diabetes treatment … Read more

NeuroBo Pharmaceuticals is a clinical stage drug development company with a focus on weight loss and a GLP-1 Dual Agonist. Its most advanced drug candidate, A-1726, is a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of obesity. The IND approval is expected soon with Phase 1 trials commencing shortly thereafter. … Read more

Brad Loncar, Founder of BiotechTV, observed during an interview in October 2023 that some people were dressed as GLP-1 agonists for Halloween. He was interviewing Dr. Eric Topol, of Scripps Research Institute, who suggested they dress up as skeletons due to how little is known about the mode of action in this class of drugs … Read more

Investment banking giant Goldman Sachs is making a major move into the life sciences sector with the launch of its first-ever dedicated fund, West Street Life Sciences I. The $650 million fund signals Goldman’s confidence in the burgeoning field and its potential for significant returns despite a recent period of setback and gloom – and … Read more